MicroStrategy
MSTR
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
Meritage Homes
MTH
US Stock MarketDetailed Quotes
SNDX Syndax Pharmaceuticals
- 13.080
- +0.230+1.79%
Close Dec 20 16:00 ET
- 12.518
- -0.562-4.29%
Post 20:01 ET
1.12BMarket Cap-3.59P/E (TTM)
13.150High12.750Low5.57MVolume12.850Open12.850Pre Close72.16MTurnover7.03%Turnover RatioLossP/E (Static)85.36MShares25.34052wk High3.05P/B1.04BFloat Cap12.75052wk Low--Dividend TTM79.18MShs Float29.860Historical High--Div YieldTTM3.11%Amplitude3.390Historical Low12.963Avg Price1Lot Size
About Syndax Pharmaceuticals Company
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development of cancer therapies. Its product candidates include SNDX-5613 and SNDX-6352. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.
Company Profile
SymbolSNDX
Company NameSyndax Pharmaceuticals
Listing DateMar 3, 2016
Issue Price12.00
Founded2005
CEOMr. Michael A. Metzger
MarketNASDAQ
Employees184
Fiscal Year Ends12-31
Address35 Gatehouse Drive,Building D,3rd floor
CityWaltham
ProvinceMassachusetts
CountryUnited States of America
Zip Code02451
Phone1-781-419-1400
Websitehttp://www.syndax.com
Company Executives
- Name
- Position
- Salary
- Michael A. Metzger
- Director and Chief Executive Officer
- 9.13M
- Catherine Madigan
- Chief Medical Officer
- 2.81M
- Steven Closter
- Chief Commercial Officer
- --
- Keith A. Goldan
- Chief Financial Officer
- 2.83M
- Dennis G. Podlesak
- Chairman of the Board
- 1.10M
- Dr. Neil Gallagher, M.D.
- President and Head of Research and Development
- 3.89M
- Dr. Aleksandra Rizo, M.D.,PhD
- Director
- --
- Jennifer Ann Jarrett
- Independent Director
- 513.85K
- William Meury
- Independent Director
- 500.27K
- Pierre Legault, C.P.A.,M.B.A.
- Independent Director
- 575.59K
- Dr. Martin H. Huber, M.D.
- Independent Director
- 516.57K
- Keith A. Katkin
- Independent Director
- 581.02K
- Luke J. Albrecht
- General Counsel and Secretary
- 2.59M
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.